| Criterion Text | Inclusion/Exclusion | Disease | Biomarker | Prior Therapy | Criterion Rule |
| --- | --- | --- | --- | --- | --- |
| Confirmed diagnosis of metastatic (Stage IV) or locally advanced, unresectable (Stage III) NSCLC of nonsquamous pathology that has relapsed or progressed | Inclusion | Non-small cell lung cancer | - | - | (Disease = "Non-small cell lung cancer" AND (Stage = "Stage IV" OR Stage = "Stage III" AND unresectable = true)) |
| PD-L1 expression status available at or after the time of diagnosis of advanced or metastatic NSCLC disease | Inclusion | Non-small cell lung cancer | PD-L1 | - | PD-L1 expression status available at or after diagnosis of advanced or metastatic NSCLC |
|  Have relapsed or progressed after prior anti-PD-(L)1 therapy as follows: | Inclusion |  |  | Anti-PD-(L)1 therapy | Has relapsed or progressed after prior anti-PD-(L)1 therapy |
| At least 12 weeks of treatment with only 1 line of anti-PD-(L)1 therapy (mono or combo) in the metastatic setting, without concomitant chemotherapy | Inclusion | None | None | Prior Therapy: Anti-PD-(L)1 therapy (mono or combo) | (Prior Therapy = "Anti-PD-(L)1 therapy (mono or combo)") |
| At least 12 weeks of single-agent durvalumab | Inclusion | None | None | Durvalumab | Durvalumab_single_agent_12_weeks |
| Symptomatic and/or untreated central nervous system (CNS) metastases or leptomeningeal disease | Exclusion | Metastatic brain disease | - | - | NOT (Disease("Metastatic brain disease") AND (Symptomatic OR Untreated)) |
| EGFR or ALK mutation | Exclusion | None | EGFR, ALK | None | !(EGFR or ALK mutation) |
| History of or active (non-infectious) pneumonitis/interstitial disease or lung fibrosis, except for Grade 1 pneumonitis from prior chemoradiation therapy (Stage III patients) | Exclusion | Pneumonitis | - | Chemoradiation therapy | - |
| History of or active autoimmune disease requiring systemic treatment in the last 6 months | Exclusion | Autoimmune disease |  |  | HasHistoryOfOrActiveAutoimmuneDisease(systemic, 6 months) |
| Persistent immune-mediated toxicity caused by checkpoint inhibitor therapy > Grade 2 | Exclusion |  |  | Checkpoint inhibitor therapy | HasPersistentImmuneMediatedToxicity(checkpoint inhibitor, > Grade 2) |
| Known active or chronic hepatitis B or C infection unless adequately treated for at least 4 weeks with no detectable viral load | Exclusion | Hepatitis B | - | - | !viral_load_detectable(hepatitis_B_or_C) |
| Known infection with human immunodeficiency virus (HIV) unless receiving antiretroviral therapy with well-controlled disease | Exclusion | HIV | - | Antiretroviral therapy | !well_controlled_disease(HIV) |
| History of life-threatening toxicity related to prior immune therapy or any toxicity resulting in permanent discontinuation from prior therapy | Exclusion | None | None | Immune therapy | Criterion Rule: NOT (Immune Therapy = None) |
| Diagnosis of immunodeficiency or any condition requiring concurrent use of systemic immunosuppressants or corticosteroids | Exclusion | Immunodeficiency |  |  | Not Immunodeficiency and not requiring concurrent use of systemic immunosuppressants or corticosteroids |
| Any other oncologic treatments administered ≤14 days (<28 days in case of checkpoint inhibitor therapy) prior to first dose of study treatment. Also, ongoing adverse effects from such treatment > Grade 1 with the exception for alopecia and Grade 2 peripheral neuropathy. | Exclusion |  |  | Chemotherapy, Targeted Therapy, Immunotherapy | Criterion Rule: (DaysSinceLastTreatment > 14) && (GradeOfAdverseEffect > 1) && (TreatmentType != "Checkpoint Inhibitor") |
| Non-study related minor surgical procedure ≤7 days, or major surgical procedure of ≤ 5 weeks prior to first dose of study treatment | Exclusion |  |  | Surgery within 7 days or 5 weeks | ¬ (Surgery ≤ 7 days ∧ Surgery ≤ 5 weeks) |
| Uncontrolled or significant cardiovascular disease | Exclusion | Cardiovascular disease |  |  | "Uncontrolled or significant cardiovascular disease" = false |
